Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: The S & P 500 is basically unchanged for the second session in a row but hovering near all-time high levels. Weighing on the index was weakness in the megacap tech stocks, with pullbacks in Amazon , Alphabet and even Meta Platforms . Unless it can climb out of its 29-point hole, a negative session seems likely for Meta Platforms. That would break a historic 20-session win streak for the stock, during which it put up 125.37 unanswered points (or dollars). We thought we were being greedy when the rally reached 18 straight positive days, prompting us to take profits last Wednesday. Stocks on our radar: Following our exit of Constellation Brands Tuesday into the Berkshire Hathaway bump, the Charitable Trust is sitting on a larger-than-usual cash position of around 11%. We’re not rushing into buy hand over first because the S & P Short Range Oscillator, our trusted momentum indicator, is nowhere near oversold, but that doesn’t mean we can’t hunt for opportunities. We’ve got our eyes on three recent laggards that have pulled back in the past couple of weeks: BlackRock , Bristol Myers Squibb and Honeywell . Shares of BlackRock have pulled back 11% from their all-time high after rival Vanguard announced on Feb. 3 it has reduced fees across 87 funds. But as we learned from BlackRock CFO Martin Small last week at a Bank of America conference, the impact from Vanguard’s pricing action is not expected to have a material impact on the company’s earnings. Based on this new information, the sell-off in BlackRock looks overdone and we remain buyers on this weakness. We already added to our position once in response to the Vanguard news. Bristol Myers was trading near its 52-week high right before the company reported its fourth-quarter results . The stock has pulled back 9% since then, and we remain buyers of this weakness. Shares lost their momentum after management offered soft 2025 guidance, but the difference between the company’s forecast and the Street mostly had to do with a difference in sales expectations for cancer treatment Revlimid, which is facing increased generic competition, and a larger than expected headwind from foreign exchange. But we remain buyers of the post-earnings pullback because the growth outlook of its new product portfolio — headlined by schizophrenia drug Cobenfy — remained intact. We also liked how management was laser focused on reducing expenses to protect its bottom line. As for Honeywell, we upgraded our rating to a buy-equivalent 1 after the recent quarter. We sold most of the position in November and January at higher prices to side step what we expected would be disappointing 2025 guidance. That turned out to be true. But with the stock trading in the low $200s, we are ready to get more constructive. Plus, we are fans of its plan to separate its gem of an aerospace business from the lagging automation division and continue on with its spinout of advanced materials unit . We have some concerns that investors will ignore this stock for a while because the breakup won’t be fully complete into the second half of 2026, but the conservative full-year outlook gives management a better opportunity to beat and raise through the year. The stock should be able to work if they can deliver. Up next: After the closing bell Tuesday, we’ll get earnings from a couple AI-related stocks in Arista Networks and Cadence Design Systems , the homebuilder Toll Brothers , and two energy producers in Devon Energy and Occidental Petroleum . Companies reporting before the opening bell Wednesday include chipmaker Analog Devices , fast food chain Wingstop , the GPS device maker Garmin , and the handmade e-commerce platform Etsy . (See here for a full list of the stocks in Jim Cramer’s Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.
